Literature DB >> 15580352

The advanced glycation end product pentosidine correlates to IL-6 and other relevant inflammatory markers in rheumatoid arthritis.

Gert E Hein1, Markus Köhler, Peter Oelzner, Günter Stein, Sybille Franke.   

Abstract

OBJECTIVE: Oxidative stress and inflammatory processes accelerate the formation of advanced glycation end products (AGE), e.g. of pentosidine. The aim of this study was to investigate the relationships between levels of pentosidine in serum and synovial fluid, proinflammatory cytokines, other markers of inflammatory activity, and the state of radiologically visible bone destruction in patients with rheumatoid arthritis (RA).
OBJECTIVES: One hundred thirty-three nondiabetic RA patients and 56 age-matched, healthy subjects were included. Serum and synovial fluid pentosidine, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and rheumatoid factor levels were determined. In 30 patients, the proinflammatory cytokines interleukin (IL)-1beta, IL-6, and TNF-alpha and the soluble receptors sIL-2R, sIL-6R, sTNF-alpha, and RI/RII were also measured.
RESULTS: Serum levels of pentosidine were on average significantly higher in RA patients than in healthy subjects and correlated significantly to ESR, CRP, and serum levels of IL-6. Serum and synovial fluid pentosidine did not show any differences. Rheumatoid factor-positive RA patients had higher pentosidine levels in the synovial fluid than rheumatoid factor-negative patients. Correlations could not be found between pentosidine and the other cytokines or cytokine receptors measured.
CONCLUSION: The binding of AGE on cell receptors induces activation of nuclear factor kappa B, resulting in enhanced synthesis of proinflammatory cytokines. Moreover, AGE generation may also lead to the formation of new, immunologically relevant epitopes at synovial proteins. Both mechanisms could contribute to initiation and perpetuation of the inflammatory and destructive processes in RA.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15580352     DOI: 10.1007/s00296-004-0518-1

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  38 in total

Review 1.  [Non-enzymatic glycation and oxidative stress in chronic illnesses and diabetes mellitus].

Authors:  P P Nawroth; A Bierhaus; G E Vogel; M A Hofmann; M Zumbach; P Wahl; R Ziegler
Journal:  Med Klin (Munich)       Date:  1999-01-15

2.  A unique antigenic determinant on collagen II closely associated with age related abnormal modification.

Authors:  C Yang; Y Acil; P K Müller
Journal:  Biochem Biophys Res Commun       Date:  1994-05-16       Impact factor: 3.575

3.  Transcription factor decoy for NFkappaB inhibits cytokine and adhesion molecule expressions in synovial cells derived from rheumatoid arthritis.

Authors:  T Tomita; H Takano; N Tomita; R Morishita; M Kaneko; K Shi; K Takahi; T Nakase; Y Kaneda; H Yoshikawa; T Ochi
Journal:  Rheumatology (Oxford)       Date:  2000-07       Impact factor: 7.580

4.  Advanced glycation endproducts: activators of cardiac remodeling in primary fibroblasts from adult rat hearts.

Authors:  S Daoud; R Schinzel; A Neumann; C Loske; D Fraccarollo; C Diez; A Simm
Journal:  Mol Med       Date:  2001-08       Impact factor: 6.354

5.  Activation of synovial fibroblasts in rheumatoid arthritis.

Authors:  R W Kinne; E Palombo-Kinne; F Emmrich
Journal:  Ann Rheum Dis       Date:  1995-06       Impact factor: 19.103

Review 6.  Hypoxia and the rheumatoid joint: immunological and therapeutic implications.

Authors:  S E Edmonds; G Ellis; K Gaffney; J Archer; D R Blake
Journal:  Scand J Rheumatol Suppl       Date:  1995

7.  Relationship between pentosidine levels in serum and urine and activity in rheumatoid arthritis.

Authors:  M Takahashi; M Suzuki; K Kushida; S Miyamoto; T Inoue
Journal:  Br J Rheumatol       Date:  1997-06

8.  A new antibody in rheumatoid arthritis targeting glycated IgG: IgM anti-IgG-AGE.

Authors:  S Ligier; P R Fortin; M M Newkirk
Journal:  Br J Rheumatol       Date:  1998-12

9.  Are advanced glycation end-product-modified proteins of pathogenetic importance in fibromyalgia?

Authors:  G Hein; S Franke
Journal:  Rheumatology (Oxford)       Date:  2002-10       Impact factor: 7.580

10.  T cell recognition of carbohydrates on type II collagen.

Authors:  E Michaëlsson; V Malmström; S Reis; A Engström; H Burkhardt; R Holmdahl
Journal:  J Exp Med       Date:  1994-08-01       Impact factor: 14.307

View more
  11 in total

1.  Interaction between oxidative stress and high-density lipoprotein cholesterol is associated with severity of coronary artery calcification in rheumatoid arthritis.

Authors:  Young Hee Rho; Cecilia P Chung; Annette Oeser; Joseph F Solus; Tebeb Gebretsadik; Ayumi Shintani; Paolo Raggi; Ginger L Milne; C Michael Stein
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-10       Impact factor: 4.794

2.  Protective effect of taraxasterol against rheumatoid arthritis by the modulation of inflammatory responses in mice.

Authors:  Shu-Hua Jiang; Li-Feng Ping; Feng-Yan Sun; Xiao-Lei Wang; Zhi-Juan Sun
Journal:  Exp Ther Med       Date:  2016-11-02       Impact factor: 2.447

3.  Increased concentration of two different advanced glycation end-products detected by enzyme immunoassays with new monoclonal antibodies in sera of patients with rheumatoid arthritis.

Authors:  Richard Vytásek; Liliana Sedová; Vladimír Vilím
Journal:  BMC Musculoskelet Disord       Date:  2010-05-03       Impact factor: 2.362

4.  Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes.

Authors:  Kazuo Nakamura; Sho-ichi Yamagishi; Hisashi Adachi; Yayoi Kurita-Nakamura; Takanori Matsui; Takafumi Yoshida; Tsutomu Imaizumi
Journal:  Mol Med       Date:  2007 Mar-Apr       Impact factor: 6.354

5.  Measurement of advanced glycation endproducts in skin of patients with rheumatoid arthritis, osteoarthritis, and dialysis-related spondyloarthropathy using non-invasive methods.

Authors:  Tomoko Matsumoto; Toshiyuki Tsurumoto; Hideo Baba; Makoto Osaki; Hiroshi Enomoto; Akihiko Yonekura; Hiroyuki Shindo; Toshio Miyata
Journal:  Rheumatol Int       Date:  2007-07-25       Impact factor: 2.631

6.  Skin autofluorescence, as marker of accumulation of advanced glycation endproducts and of cumulative metabolic stress, is not increased in patients with systemic sclerosis.

Authors:  M E Hettema; H Bootsma; R Graaff; R de Vries; C G M Kallenberg; A J Smit
Journal:  Int J Rheumatol       Date:  2011-09-29

7.  Tumor necrosis factor receptor 2 as a possible marker of COPD in smokers and ex-smokers.

Authors:  Laura Miranda de Oliveira Caram; R Ferrari; D L Nogueira; Mrm Oliveira; F V Francisqueti; S E Tanni; C R Corrêa; I Godoy
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-07-07

8.  Possible rheumatoid arthritis subtypes in terms of rheumatoid factor, depression, diagnostic delay and emotional expression: an exploratory case-control study.

Authors:  Taavi Tillmann; Rajeev Krishnadas; Jonathan Cavanagh; K V Petrides
Journal:  Arthritis Res Ther       Date:  2013-03-21       Impact factor: 5.156

9.  Serum and bone pentosidine in patients with low impact hip fractures and in patients with advanced osteoarthritis.

Authors:  Jan Vaculík; Martin Braun; Pavel Dungl; Karel Pavelka; Jan J Stepan
Journal:  BMC Musculoskelet Disord       Date:  2016-07-22       Impact factor: 2.362

Review 10.  Profile of sarilumab and its potential in the treatment of rheumatoid arthritis.

Authors:  Maria Gabriella Raimondo; Martina Biggioggero; Chiara Crotti; Andrea Becciolini; Ennio Giulio Favalli
Journal:  Drug Des Devel Ther       Date:  2017-05-24       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.